• Metabolic disorder of multiple causes characterized by chronic hyperglycemia and disorders of carbohydrate, fat, and protein metabolism • Results from defects in insulin secretion (type 1), insulin action (type 2), or combination of these factors • World Health Organization and American Diabetes Association diagnostic criteria: Ⅲ Fasting plasma glucose Ն126 mg/dL (Ն7.0 mmol/L) or fasting whole-blood glucose level Ն110 mg/dL (Ն6.1 mmol/ L), or a Ⅲ 2-hour post-glucose-load plasma glucose Ն200 mg/dL (Ն11.1 mmol/L; 180 mg/dL [10.0 mmol/L] if whole blood), or a Ⅲ Random plasma glucose Ͼ200 mg/dL (Ͼ11.1 mmol/L) on Ͼ1 occasion Ⅲ "Prediabetic" stage: fasting plasma glucose between 100 and 126 mg/dL (5.6 and 7.0 mmol/L) increasingly recognized as risk factor for end-organ complications; evidence supports lifestyle interventions to prevent or delay onset of diabetes 
DN PATHOLOGY

General
• Diabetic kidneys generally increased in size (between 10% and 30% above age-, sex-, and race-matched controls) on ultrasound and gross pathologic evaluation due to glomerular and tubular hypertrophy, rather than hyperplasia
Indications for Biopsy
• Accelerated disease kinetics compared with earlier description in "Diabetic Nephropathy: General" section • Absence of extrarenal end-organ damage • Concomitant nondiabetic lesions are rare, although higher incidences have been reported in selected populations characterized by atypical clinical presentations 
